Bausch Health Companies (TSE:BHC) Rating Increased to Hold at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Bausch Health Companies (TSE:BHC) to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

Bausch Health Companies Stock Performance

BHC stock opened at C$6.44 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 1.32 and a debt-to-equity ratio of -1,009.96. The company has a market capitalization of C$2.41 billion, a price-to-earnings ratio of -1.99, a P/E/G ratio of 0.21 and a beta of 0.97. Bausch Health Companies has a 12 month low of C$6.10 and a 12 month high of C$11.97. The firm has a 50 day moving average of C$7.07 and a two-hundred day moving average of C$7.71.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. Bausch Health Companies had a negative net margin of 13.54% and a positive return on equity of 120.43%. The business had revenue of C$3.51 billion for the quarter. As a group, equities analysts anticipate that Bausch Health Companies will post 5.5472637 EPS for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.